Reuters logo
in 2 months
BRIEF-Valbiotis says Phase I/II Valedia study validate safety and first proof of efficacy
June 9, 2017 / 5:37 AM / in 2 months

BRIEF-Valbiotis says Phase I/II Valedia study validate safety and first proof of efficacy

June 9 (Reuters) - VALBIOTIS SAS

* ‍WILL PRESENT RESULTS OF ITS PHASE I/II CLINICAL STUDY ON ACTIVE INGREDIENT OF VALEDIA, TOTUM-63​

* RESULTS VALIDATE SAFETY AND A FIRST PROOF OF EFFICACY FOR VALEDIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below